Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the company and Janssen had, by failing to obtain a commercial license from Xoma ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

Tremfya’s reign atop the TV pharma ad rankings continued for yet another month as the Johnson & Johnson brand topped iSpot.tv’s list for October. Tremyfa achieved an impressions share of voice (SOV) ...